FDA's Pe­ter Marks says some sec­ondary can­cer cas­es af­ter CAR-T ther­a­py may be 'causal,' but ben­e­fits still out­weigh risks: #JPM24

The FDA be­lieves that the ben­e­fit of CAR-T ther­a­pies con­tin­ues to out­weigh their risks amid an on­go­ing in­ves­ti­ga­tion on cas­es of sec­ond blood can­cers de­vel­op­ing in pa­tients who re­ceive the cell ther­a­pies, ac­cord­ing to se­nior FDA of­fi­cial Pe­ter Marks.

The FDA is now in­ves­ti­gat­ing 22 cas­es of blood can­cer de­vel­op­ing af­ter CAR-T cell ther­a­py treat­ment, said Marks, the di­rec­tor of the FDA’s Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search, on Mon­day at an Al­liance for Re­gen­er­a­tive Med­i­cine event. “Al­though se­quenc­ing is not avail­able for all of them, in at least a few of the cas­es we know that the CAR con­struct is in the ma­lig­nant clone, which re­al­ly sug­gests that there was prob­a­bly an as­so­ci­a­tion there,” Marks said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER